Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$115.95

-0.52 (-0.45%)

(As of 09:15 AM ET)

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
0

Hold
1

Buy
6

Based on 7 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for NVO.

Consensus Price Target

$144.50
24.08% Upside

According to the 7 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $144.50. The highest price target for NVO is $160.00, while the lowest price target for NVO is $115.00. The average price target represents a forecasted upside of 24.08% from the current price of $115.95.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 10/24/23 to 10/23/24	1 Month Ago 9/24/23 to 9/23/24	3 Months Ago 7/26/23 to 7/25/24	1 Year Ago 10/24/22 to 10/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$144.50	$145.17	$145.67	$60.83
Forecasted Upside	24.08% Upside	17.34% Upside	13.97% Upside	-37.60% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

War on Elon Escalates… (Ad)

Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

Click here to learn how you can benefit from its widespread distribution.

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	24.08% Upside	8,467.51% Upside	7.98% Upside
News Sentiment Rating	Positive News See Recent NVO News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
10/17/2024	BMO Capital Markets 4 of 5 stars	Lower Target	Outperform ➝ Outperform	$160.00 ➝ $156.00	+31.57%
10/10/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+36.43%
6/10/2024	Argus 3 of 5 stars	Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$156.00	+17.58%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$120.00	+13.75%
1/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$32.50 ➝ $36.25	+11.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:25 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 18, 2024. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Novo Nordisk's stock price has shown resilience, currently trading at a stable level, indicating potential stability in the market.
Novo Nordisk has a strong track record of innovation in the pharmaceutical industry, consistently developing new products and treatments.
The company has a robust financial position with a high return on equity, indicating efficient use of shareholder funds.
Novo Nordisk's consistent revenue growth and profitability demonstrate its ability to navigate market challenges effectively.
With a diverse product portfolio and global presence, Novo Nordisk is well-positioned to capitalize on emerging market opportunities.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Market volatility and regulatory uncertainties in the pharmaceutical sector could impact Novo Nordisk's stock performance.
Intense competition in the industry may put pressure on Novo Nordisk's market share and pricing power.
Fluctuations in currency exchange rates could affect Novo Nordisk's international operations and financial results.
Dependency on a few key products for a significant portion of revenue exposes Novo Nordisk to risks associated with product concentration.
Changes in healthcare policies and regulations globally could impact Novo Nordisk's pricing strategies and market access.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $144.50, with a high forecast of $160.00 and a low forecast of $115.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 24.62% based on their 12-month stock forecasts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, and Cantor Fitzgerald in the past 90 days.
: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how NVO compares to other companies.